How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD

被引:62
作者
Hong, Kimberly N. [1 ]
Fuster, Valentin [1 ]
Rosenson, Robert S. [1 ]
Rosendorff, Clive [1 ]
Bhatt, Deepak L. [2 ,3 ]
机构
[1] Mt Sinai Hlth Syst, Icahn Sch Med, Dept Cardiol, New York, NY USA
[2] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA USA
关键词
cardiovascular disease; diabetes; hyperlipidemia; hypertension; primary prevention; CORONARY-HEART-DISEASE; CARDIOVASCULAR RISK; LDL-CHOLESTEROL; TASK-FORCE; SUBCLINICAL ATHEROSCLEROSIS; MICROVASCULAR DYSFUNCTION; GLYCOSYLATED HEMOGLOBIN; HYPERTENSIVE PATIENTS; CLINICAL-PRACTICE; AMERICAN-COLLEGE;
D O I
10.1016/j.jacc.2017.09.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes, hyperlipidemia, and hypertension are modifiable risk factors that predict cardiovascular disease events. The effect of these risk factors on incident cardiovascular disease increases with progressively higher levels of glucose, low-density lipoprotein cholesterol, and blood pressure. The thresholds for initiating treatment of these modifiable risk factors and the optimal goals of risk factor modification are a focus of primary prevention research. Although an aggressive approach is appealing, adverse events may occur, and potential physiological barriers may exist. This paper discusses primary prevention of coronary heart disease that may be achieved through modification of diabetes, hyperlipidemia, and hypertension by summarizing current guidelines and pertinent clinical trial data from intervention trials that included a primary prevention cohort. (C) 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
引用
收藏
页码:2171 / 2185
页数:15
相关论文
共 96 条
[1]  
[Anonymous], LANCET
[2]  
[Anonymous], 2016, COCHRANE DB SYST REV
[3]  
[Anonymous], 2016, LANCET, DOI DOI 10.1016/S0140-6736(15)01225-8
[4]  
[Anonymous], 2017, COCHRANE DATABASE SY
[5]  
[Anonymous], 2017, American Heart Association backs current BP treatments. Retrieved April 7, 2017
[6]  
[Anonymous], EXT OLE STUD ASS SAF
[7]   Prevalence, Impact, and Predictive Value of Detecting Subclinical Coronary and Carotid Atherosclerosis in Asymptomatic Adults The BioImage Study [J].
Baber, Usman ;
Mehran, Roxana ;
Sartori, Samantha ;
Schoos, Mikkel Malby ;
Sillesen, Henrik ;
Muntendam, Pieter ;
Garcia, Mario J. ;
Gregson, John ;
Pocock, Stuart ;
Falk, Erling ;
Fuster, Valentin .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (11) :1065-1074
[8]   Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[9]   Intensive LDL-cholesterol lowering therapy and neurocognitive function [J].
Banach, Maciej ;
Rizzo, Manfredi ;
Nikolic, Dragana ;
Howard, George ;
Howard, VirginiaJ. ;
Mikhailidis, DimitriP. .
PHARMACOLOGY & THERAPEUTICS, 2017, 170 :181-191
[10]   An assessment by the Statin Liver Safety Task Force: 2014 update [J].
Bays, Harold ;
Cohen, David E. ;
Chalasani, Naga ;
Harrison, Stephen A. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (03) :S47-S57